Psychedelics and ketamine as plasticity openers, not magic cures
September 29, 2026 · 23 min read
Ketamine, psilocybin and MDMA work through different receptors, yet the sources describe each as opening a temporary window of neuroplasticity that therapy and practice must then use. It explains why effects fade without integration and why a neurosurgeon calls drugs, not electrodes, today's best plasticity tool.
The rules, numbers and steps worth keeping in front of you.
- All three drugs open a window for brain change. None is the change itself.
- Ketamine blocks NMDA receptors, yet triggers burst firing and BDNF release.
- A single ketamine dose fades in about three days to a week.
- Repeated clinical sessions can bring weeks or months of relief.
- Huberman: the trip may not be what heals. Blocking opioid receptors removed the benefit, not the high.
- Psilocybin activates serotonin 2A receptors and increases cross-brain connectivity.
- Huberman: psychedelics are a wedge under the boulder of plasticity.
- Plasticity is not automatically good. Brain injury also rewires the brain.
- MDMA on its own does not cure PTSD. It augments talk therapy.
- Carhart-Harris: trust in the therapists predicts the experience and the outcome.
- Carhart-Harris: relapse by three months is common in treatment-resistant depression.
- Microdosing ketamine or LSD has no good evidence.
- MacDougall: drugs reach the whole brain, and electrodes cannot.
- Use qualified clinicians only, and never stop antidepressants on your own.
This is the short form. The full insight has every expert's reasoning, their own words and the sources.